316 related articles for article (PubMed ID: 32326111)
1. Role of Genetic Variations in the Hepatic Handling of Drugs.
Marin JJG; Serrano MA; Monte MJ; Sanchez-Martin A; Temprano AG; Briz O; Romero MR
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326111
[TBL] [Abstract][Full Text] [Related]
2. Exome-Wide Analysis of the DiscovEHR Cohort Reveals Novel Candidate Pharmacogenomic Variants for Clinical Pharmacogenomics.
Pandi MT; Williams MS; van der Spek P; Koromina M; Patrinos GP
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32443490
[TBL] [Abstract][Full Text] [Related]
3. Liver genomic responses to ciguatoxin: evidence for activation of phase I and phase II detoxification pathways following an acute hypothermic response in mice.
Morey JS; Ryan JC; Bottein Dechraoui MY; Rezvani AH; Levin ED; Gordon CJ; Ramsdell JS; Van Dolah FM
Toxicol Sci; 2008 Jun; 103(2):298-310. PubMed ID: 18353800
[TBL] [Abstract][Full Text] [Related]
4. Effect of dietary α-lipoic acid on the mRNA expression of genes involved in drug metabolism and antioxidation system in rat liver.
Ide T
Br J Nutr; 2014 Aug; 112(3):295-308. PubMed ID: 24787548
[TBL] [Abstract][Full Text] [Related]
5. Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes.
Ghose R; Guo T; Vallejo JG; Gandhi A
Drug Metab Dispos; 2011 May; 39(5):874-81. PubMed ID: 21303924
[TBL] [Abstract][Full Text] [Related]
6. Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver.
Wu KC; Cui JY; Klaassen CD
PLoS One; 2012; 7(7):e39006. PubMed ID: 22808024
[TBL] [Abstract][Full Text] [Related]
7. Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes.
Chen C; Han YH; Yang Z; Rodrigues AD
Xenobiotica; 2011 Jun; 41(6):476-85. PubMed ID: 21381897
[TBL] [Abstract][Full Text] [Related]
8. Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors.
Emami Riedmaier A; Burk O; van Eijck BA; Schaeffeler E; Klein K; Fehr S; Biskup S; Müller S; Winter S; Zanger UM; Schwab M; Nies AT
Pharmacogenomics J; 2016 Aug; 16(4):341-51. PubMed ID: 26239079
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
10. [Advances in the study of organic anion transporting polypeptide 1B3].
Li X; Li Y
Yao Xue Xue Bao; 2011 Nov; 46(11):1279-85. PubMed ID: 22260016
[TBL] [Abstract][Full Text] [Related]
11. Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems.
Nakata K; Tanaka Y; Nakano T; Adachi T; Tanaka H; Kaminuma T; Ishikawa T
Drug Metab Pharmacokinet; 2006 Dec; 21(6):437-57. PubMed ID: 17220560
[TBL] [Abstract][Full Text] [Related]
12. The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Durmus S; van Hoppe S; Schinkel AH
Drug Resist Updat; 2016 Jul; 27():72-88. PubMed ID: 27449599
[TBL] [Abstract][Full Text] [Related]
13. Multispecific drug transporter Slc22a8 (Oat3) regulates multiple metabolic and signaling pathways.
Wu W; Jamshidi N; Eraly SA; Liu HC; Bush KT; Palsson BO; Nigam SK
Drug Metab Dispos; 2013 Oct; 41(10):1825-34. PubMed ID: 23920220
[TBL] [Abstract][Full Text] [Related]
14. Aflatoxin B
Deng J; Zhao L; Zhang NY; Karrow NA; Krumm CS; Qi DS; Sun LH
Mutat Res Rev Mutat Res; 2018; 778():79-89. PubMed ID: 30454686
[TBL] [Abstract][Full Text] [Related]
15. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.
Bachmakov I; Glaeser H; Fromm MF; König J
Diabetes; 2008 Jun; 57(6):1463-9. PubMed ID: 18314419
[TBL] [Abstract][Full Text] [Related]
16. De novo assembly and transcriptome characterization of the freshwater prawn Palaemonetes argentinus: Implications for a detoxification response.
García CF; Pedrini N; Sánchez-Paz A; Reyna-Blanco CS; Lavarias S; Muhlia-Almazán A; Fernández-Giménez A; Laino A; de-la-Re-Vega E; Lukaszewicz G; López-Zavala AA; Brieba LG; Criscitello MF; Carrasco-Miranda JS; García-Orozco KD; Ochoa-Leyva A; Rudiño-Piñera E; Sanchez-Flores A; Sotelo-Mundo RR
Mar Genomics; 2018 Feb; 37():74-81. PubMed ID: 28923556
[TBL] [Abstract][Full Text] [Related]
17. Clinical importance of the cytochromes P450.
Nebert DW; Russell DW
Lancet; 2002 Oct; 360(9340):1155-62. PubMed ID: 12387968
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).
Letschert K; Keppler D; König J
Pharmacogenetics; 2004 Jul; 14(7):441-52. PubMed ID: 15226676
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
[TBL] [Abstract][Full Text] [Related]
20. Functional assessment of genetic variants located in the promoter of SHP1 (NR0B2).
Prestin K; Olbert M; Hussner J; Völzke H; Meyer Zu Schwabedissen HE
Pharmacogenet Genomics; 2017 Nov; 27(11):410-415. PubMed ID: 28873070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
